|Support type:||Scholarships in Brazil - Scientific Initiation|
|Effective date (Start):||January 01, 2012|
|Effective date (End):||December 31, 2012|
|Field of knowledge:||Biological Sciences - Microbiology|
|Principal researcher:||Silvia Beatriz Boscardin|
|Grantee:||Tamara Silva Frias Garcia|
|Home Institution:||Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil|
In the last decade, a strategy for the targeting antigens to dendritic cells (DCs) in vivo has been developed successfully in animal models. DCs are central cells in the process of inducing immunity against various pathogens and tolerance. Our strategy is to use a monoclonal antibody against a receptor on the surface of DC fused with the antigen of interest. The administration of low doses of chimeric antibody, in the presence of a DC maturation stimuli, is able to activate antigen-specific T cells and induce the production of high titers of antibodies. The CD8+DEC205+ DC subpopulation expresses the endocytic receptor DEC205 and also the CD8 molecule alpha chain. A large number of recent studies demonstrated that immunization of animals with anti-DEC205 fused with different proteins in the presence of a maturation stimulus for DCs is capable of inducing strong immune response (both cellular and humoral), and in some cases, protection against challenge with the pathogen. The human papilloma virus (HPV) is the main etiological agent of cervical cancer and other cancers. The protein E7 encoded by HPV is involved in cell cycle control. Recently, an experimental strategy based on a DNA vaccine encoding the E7 protein of HPV-16 (the most relevant viral type epidemiologically) was successfully developed. The vaccine contains the E7 gene of HPV-16 fused to glycoprotein D (gD) of the herpes simplex virus type 1 (HSV-1).In this project, we intend to clone the E7 protein and a protein formed by the E7 protein and gD of herpes simplex virus type 1 fused with the sequence of the anti-DEC205 antibody, produce the hybrid antibody and test its binding capacity to cells that express the DEC205 receptor. Also, we intend to produce an isotype control that is unable to bind to the DEC205 receptor.